Form 8-K · Current Report · Filed 2025-09-08
Johnson & Johnson Appoints John Morikis to Board of Directors
Johnson & Johnson announced on September 8, 2025, the appointment of John Morikis, retired Chairman, President, and CEO of The Sherwin-Williams Company, to its Board of Directors.
- Filer
- Johnson & Johnson JNJ · NYSE
- Filed
- Accession
- 0000200406-25-000190
- CIK
- 0000200406
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Mr. Morikis, a seasoned leader with over four decades of experience in the paint industry, will serve on the Audit Committee and Compensation & Benefits Committee.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$178.43
Next session
-0.8%
Since filing
+43.7%
Latest close
$256.35
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from JNJ reporting the same item, with the next session's move:
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Never miss another JNJ filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.